Mark Yarchoan, Associate Professor at Johns Hopkins Hospital and Co-Founder and CSO at Adventris Pharmaceuticals, shared on X:
“The era of non-specific checkpoint intensification is finally coming to a close, whereas neoantigen-specific therapies are just getting started.
I expect the positive Moderna vaccine P3 trial is just the beginning.”
You can also read: Merck and Moderna’s Intismeran Autogene Plus Keytruda Meets Phase 3 RFS and DMFS Endpoints in Resected Melanoma
